Business Wire

Global Health Progress Launched to Drive Cross-sectoral Collaborations in Support of the Sustainable Development Goals (SDGs)

25.10.2019 02:00:00 EEST | Business Wire | Press release

Share

To support the SDGs, with a particular focus on SDG 17: Partnership for The Goals, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has launched Global Health Progress. The knowledge hub highlights industry contributions to the SDGs and enhances opportunities for further collaboration.

2020 marks the 10-year countdown to the SDG deadline. Countries have made progress towards achieving the goals; however, complex health and wellbeing challenges remain – from poverty and inequality to climate change. Further, many countries are now faced with a double burden of disease – as they continue to tackle infectious disease challenges, they also battle with an increasing prevalence of non-communicable diseases (NCDs) – which present new issues in implementing effective and sustainable solutions for health.

Global Health Progress highlights over 200 collaborations which use innovative approaches to tackle global health challenges. The collaborations are helping to bring different actors together – governments, academia, multilateral organizations, other private sector companies, local NGOs and more – to catalyze cross-sector initiatives to tackle health related challenges, as well as address gender equality and education issues. A range of program strategies are being used to address systemic health issues and lay foundations to sustain program gains. In consultation with local actors, IFPMA member companies are fostering local ownership of programs and designing programs according to country’s specific health needs and existing health system infrastructure.

The collaborations are transforming traditional approaches to partnerships. For more information, visit Global Health Progress at www.globalhealthprogress.org

About IFPMA

IFPMA represents innovative biopharmaceutical companies and associations across the globe. The biopharmaceutical industry’s two million employees discover, develop, and deliver medicines and vaccines that improve the lives of patients worldwide. Based in Geneva, IFPMA has official relations with the UN and contributes industry expertise to help the global health community find solutions that improve health for populations around the world.

For more information, visit IFPMA at www.ifpma.org 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Unjela Kaleem, Director of Communications
u.kaleem@ifpma.org
+41223383200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The LYCRA Company Launches LYCRA ® ADAPTIV fiber for Nonwovens, Advancing Comfort and Fit in Disposable Hygiene at INDEX™ 2613.5.2026 15:00:00 EEST | Press release

The LYCRA Company, a leader in innovative and sustainable fibers for apparel and personal care, today announced the official global launch of LYCRA® ADAPTIV fiber for nonwovens at INDEX™ 26, in Geneva, Switzerland, May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514856391/en/ At INDEX™ 26 in Geneva, The LYCRA Company debuts LYCRA® ADAPTIV fiber for nonwovens, a next-generation stretch solution that delivers enhanced comfort, a secure fit, and helps enable inclusive sizing for baby diapers, adult incontinence, and feminine care products. This breakthrough stretch fiber, already trusted by leading global apparel brands, now ushers in a new era of comfort, fit, and performance for baby diapers, disposable hygiene products, adult incontinence, and feminine care. LYCRA® ADAPTIV fiber is engineered to address key unmet needs in hygiene and personal care. According to the company’s proprietary research, these include f

Adtran expands SDG 8700 Series to deliver Wi-Fi 7 at scale13.5.2026 15:00:00 EEST | Press release

Adtran today announced an expansion of its SDG 8700 Series, extending Wi-Fi 7 across a broader range of residential service tiers and deployment models. The expanded portfolio introduces new 2.5Gbit/s and 10Gbit/s Wi-Fi 7 platforms designed to support the full spectrum of multigigabit services – from entry-level offerings to premium tiers – across residential, SMB, MDU and community Wi-Fi deployments. As service providers enter a new access refresh cycle, Wi-Fi 7 is rapidly becoming a baseline requirement rather than a premium differentiator. Adtran’s expanded SDG 8700 portfolio enables providers to deploy next-generation Wi-Fi more broadly and consistently without compromising subscriber experience or changing operational models. The launch also builds on the FCC’s recent conditional approval of Adtran’s SDG portfolio, supporting continued broadband rollout momentum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202605130036

Austrian Broadband Operator Deploys Vecima’s Entra ® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS ® Network13.5.2026 14:45:00 EEST | Press release

Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services. After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure. Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, combining a modern microservices architecture with commercial off-the-shelf (COTS) hardware to deliver next-generation flexibility while enhan

Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 14:30:00 EEST | Press release

Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables operators—particularly regional and emerging providers—to deploy scalable, high-performance networks with reduced complexity and faster time to revenue. The joint Vecima, Incognito, and BM COM Broadband-in-a-Box solution integrates: Vecima’s Entra® XGS-PON platform, delivering scalable, high-

Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days * Without Regulatory Risks13.5.2026 14:05:00 EEST | Press release

Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (NDA). "Following recent FDA interactions, we are advancing our NDA submission for CNM-Au8 with NfL biomarker concordance evidence as a core compon

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye